The Biosimilar Contract Manufacturing Market is witnessing strong growth as manufacturers respond to increasing demand for affordable and high-quality biologic medicines. Market Research Future estimates that the market will increase from USD 9.19 billion in 2025 to approximately USD 51.9 billion by 2035, representing a CAGR of 18.9%.

One of the major trends shaping the industry is the adoption of advanced biomanufacturing technologies. Single-use systems, improved cell-culture techniques, continuous manufacturing, and process optimization are helping contract manufacturers increase production efficiency while maintaining quality and regulatory compliance.

Another important trend is the increasing use of outsourcing. Pharmaceutical companies can collaborate with contract development and manufacturing organizations to reduce infrastructure requirements, access specialized expertise, and accelerate biosimilar development and commercialization. Collaborative partnerships are therefore becoming increasingly important across the industry.

Oncology represents a significant application segment, supported by the growing global demand for cost-effective cancer treatments. Biosimilars are also increasingly being developed for blood disorders, chronic diseases, autoimmune disorders, and rheumatoid arthritis.

Regionally, North America held more than 45% of global revenue in 2024, while Europe represented another major market. Asia-Pacific is expected to provide attractive opportunities because of growing healthcare investments, expanding pharmaceutical industries, and increasing demand for affordable biologic therapies.